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Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and
adolescence. Despite intergroup clinical trials conducted in Europe and North America,
outcomes for high risk patients with this disease have not significantly improved in the last
several decades, and survival of metastatic or relapsed disease remains extremely poor.
Accrual into new clinical trials is slow and difficult, so in vitro cell-line research and in vivo
xenograft models present an attractive alternative for preclinical research for this cancer
type. Currently, 30 commonly used human RMS cell lines exist, with differing origins, kary-
otypes, histologies, and methods of validation. Selecting an appropriate cell line for RMS
research has important implications for outcomes. There are also potential pitfalls in using
certain cell lines including contamination with murine stromal cells, cross-contamination
between cell lines, discordance between the cell line and its associated original tumor,
imposter cell lines, and nomenclature errors that result in the circulation of two or more pre-
sumed unique cell lines that are actually from the same origin.These pitfalls can be avoided
by testing for species-specific isoenzymes, microarray analysis, assays for subtype-specific
fusion products, and short tandem repeat analysis.
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INTRODUCTION
Rhabdomyosarcoma (RMS) is a malignancy that arises from skele-
tal muscle precursors (1). It is the most common type of soft tissue
sarcoma in children and adolescents less than 20 years old, with an
incidence of 4.5 cases per million children/adolescents per year (2).
There are two major subtypes of RMS, embryonal and alveolar,
which differ markedly in their outcomes. Embryonal RMS usually
presents in children less than 10 years old and has a 5-year survival
of close to 75%. Alveolar RMS, on the other hand, occurs at about
the same incidence throughout childhood and adolescence and is
associated with a poorer prognosis with a 5-year survival rate of
less than 50%. Patients with refractory or relapsed RMS have an
even worse prognosis, with survival ranging from 10 to 30% (3).
Despite numerous clinical trials, outcomes for high risk RMS
have not improved significantly in the last 30 years. Given the rel-
atively small population of children diagnosed with this disease
annually, and the number and timing of new clinical trials, testing
new potential treatment agents is limited. In vitro cell-line research
and in vivo xenograft models aid in the basic and preclinical effort
to identify potential new treatments. If shown promising, these
agents can then be taken into human clinical trials, and compared
to standard of care agents. The Pediatric Preclinical Testing Panel
(PPTP) is an initiative formed by the National Cancer Institute,
working to further characterize and validate available cell lines in
multiple kinds of pediatric cancer, including RMS so that preclin-
ical evaluations of new chemotherapeutic agents can be tested (4).
Currently, there are 18 embryonal and 12 distinct alveolar human
RMS cell lines described in the literature that have been used in
more than one study by more than one research group. They differ
in their origins, histologies, karyotypes, and methods of validation.
They are described below and summarized in Table 1. There are
also 16 human RMS cell lines that have been described and used
by single research groups (5–17); these are listed in Table 2. [Of
note, during revisions of this article an independent list of human
and murine RMS cell lines was published (18).] The current article
aims to summarize the published RMS cell lines, aid scientists in
deciding which lines may be applicable to their research projects,
and highlight important historical information and limitations for
specific cell lines.
EMBRYONAL RMS CELL LINES
CCA
CCA was derived from the biopsy of a “vesical” recurrence of
embryonal RMS in an 8-year-old Caucasian male (19). Mul-
tiple chromosomal rearrangements were identified upon kary-
otype analysis, with additional defects on chromosomes 1, 4, 6,
8, 9, 10, 11, 12, and 13 (20). CCA cells express vimentin and
desmin. These cells can be used to generate xenografts in nude
mice subcutaneously or intramuscularly, and form lung metas-
tases when injected intravenously after pretreatment of the mice
with cyclophosphamide. CCA cells harbor a Q61L mutation in
KRAS (21). CCA has been grown in modified Dulbecco’s medium
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Table 1 | Human RMS cell lines reported and used by multiple research groups.
Cell lines Origin Previous
treatment
Karyotype/gene fusion status STR
EMBRYONAL HISTOLOGY
CCA “Vesical” recurrence Unknown Multiple chromosomal rearrangements,
Q61L mutation of KRAS
Unknown
CT-TC Primary tumor Unknown Unknown Unknown
HX170c Paratesticular tumor of 5-year-old male at recurrence Yes Near diploid Unknown
JR-1 Lung metastasis 7-year-old female Yes Near tetraploid,TP53 mutation Unknown
KF-RMS-1 Bone marrow metastasis Unknown Unknown Unknown
RD Pelvic mass 7-year-old female Yes 51-hyperdiploid, MYC amplification, Q61H
mutation of NRAS,TP53 mutation
Yes
RH6 Lymph node metastasis 16-year-old male Unknown Unknown Unknown
RH12 Buttock tumor No Multiple chromosomal rearrangements Unknown
RH14 Inguinal tumor at recurrence Yes Unknown Unknown
RH36 (Birch) Paratesticular relapse 15-year-old male Yes Unknown Unknown
RMS559/R31 Unknown Unknown V550L mutation of FGFR4 Unknown
RMS-YM Abdominal mass 2-year-old male Unknown Multiple chromosomal rearrangements,
upregulation of MDM2, FGFR1
Unknown
RUCH2 Botryoid vaginal mass 15-month-old female No Multiple chromosomal rearrangements Unknown
RUCH3 Unknown Unknown Unknown Unknown
SCMC-RM2 Bone marrow metastasis of 11-year-old female Yes NMYC amplification
SMS-CTR Pelvic mass 1-year-old No Hypertriploid, t(1;13)(q21;q14) and
t(2;13)(p25;q14)*
Yes
TTC442 Unknown Unknown Unknown Unknown
TTC516 Unknown Unknown Unknown Unknown
ALVEOLAR HISTOLOGY
CW9019 Unknown Unknown t(1;13) Unknown
D-RHA1 Unknown Unknown Unknown Unknown
KFR Bone marrow metastasis No Pseudodiploid, t(2;13)(q35;q14)$ Unknown
RH5 Unknown No Unknown Unknown
RH10 Perineal relapse 5-year-old female Yes Hyperdiploid, t(2;13) Unknown
RH18 fusion-negative Perineal mass 2-year-old No Amplification of 12q13–15 region including
MDM2
Yes
RH18 fusion-positive Perineal mass 2-year-old No t(2;13) Yes
RH28 (RH3) Axillary metastasis 17-year-old male No Near tetraploid t(2;13) Yes
RH30 (RMS13) Bone marrow metastasis 16-year-old male No t(2;13),TP53 mutation, amplification of
12q13–15 region including CDK4
Yes
RH41 (RH4) Lung metastasis 7-year-old female Yes t(2;13),TP53 mutation Yes
RH65 Relapse 18-year-old female Yes Unknown Unknown
RMZ-RC2 Bone marrow metastasis 2-year-old Yes PAX7-FOXO1, NMYC amplification Unknown
TC212 Bone marrow metastasis 16-year-old male Yes t(2;13)(q35;q14)$ Unknown
*These are not the characteristic translocations associated with ARMS. See text.
$There was a time that the 2q breakpoint was assigned to q35 or q37; this has now been resolved as a q35 breakpoint. See text.
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Table 2 | Additional human RMS cell lines reported and used by a single research group.
Cell lines Origin Previous
treatment
Karyotype Additional
information
Reference
EMBRYONAL HISTOLOGY
DI-OH1 Primary tumor, pediatric male Unknown 50, XY, +2, +8, +11 Undetectable
telomerase activity
Kleideiter et al. (8)
VK Primary tumor of 20-year-old
female with localized disease
None 46, XX, t(1;11)(p36.31;p11.2),
t(10;11)(q22.3;p11.2),
t(1;10)(p36.31;q22.3), t(2;17)(q23;p13.3),
t(4;19)(q35.1;q13.1),
t(14;17)(q32.3;q21.31)
Urumov and
Manolova (11)
RMS-GR Relapsed urogenital tract
tumor of 75-year-old male
Yes 59, XY, −1, +der(1)t(1;?)(q31;?),
+del(1)(p13), +del(3)(p13), +del(3)(p13),
der(3)t(3;19)(p11;q11),
+der(8)t(8;?)(p23;?), +M
Upregulation of
mdr1
Fernandez et al. (6)
TS-RM-1 Unknown Unknown Chromosome number 88−98
der(3)t(1;3)(q12;p12–14), 16q-, 17q+, and
21q+
Kaneko et al. (13)
YN 15-year-old male with
paratesticular tumor
Unknown Unknown Motoyama et al.
(12)
ALVEOLAR HISTOLOGY
CB-NJR Unknown Unknown Unknown Ozkaynak et al. (10)
FL-OH1 Primary tumor, pediatric male Unknown 60–89, XY, many clonal and non-clonal
aberrations, negative for t(1;13), t(2;13)
High telomerase
activity
Kleideiter et al. (8)
HA-OH1 Relapsed tumor, pediatric
female
Unknown 78–87, XXX, der(1), t(1;13), der(1), t(1;13),
i(q), del(3), 4q+, del(6), −13, [cp4]
Low telomerase
activity
Kleideiter et al. (8)
HUMEMS 13-year-old female with breast
primary, cell line established
from pleural fluid
t(2;13) Ohi et al. (14)
NRS-1 7-year-old female with
forearm primary
Unknown t(2;13) Ogose et al. (15)
RH7 Primary tumor Unknown Morton and Potter
(23)
UISO-RS-3 28-year-old female with
buttock primary, cell line
established from a malignant
pleural effusion
Yes 43–49, X, Philadelphia 22 chromosome
(70% of metaphase spreads)
Madsen et al. (10)
Not named 14-year-old female with chest
wall primary, cell line
established from malignant
effusion
Unknown 41–49, t(2,13)(q37;q14), double minute
chromosomes
Garvin et al. (7)
PLEOMORPHIC HISTOLOGY
HS-RMS-1 26-year-old male with gluteal
tumor
Unknown Pseudotetraploid Sonobe et al. (16)
HS-RMS-2 85-year-old female with
gluteal tumor
Unknown 8 amplified regions including oncogenes
JUN, MYC, CCND1, INT2, MDM2, and
MALT
Takaoka et al. (17)
UNKNOWN HISTOLOGY
HUS-2 80-year-old female with chest
wall mass
No Modal chromosome number of 58 Cook et al. (5)
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(DMEM) with 10% fetal bovine serum (FBS) (22). As with cell
culture in general, it is up to the investigator whether prophylactic
antibiotics penicillin and streptomycin are to be included during
routine culture.
CT-TC
This cell line was derived from a primary tumor with an embryonal
histology and expresses MyoD, myogenin, and desmin (at very low
levels). It was originally developed by Dr. Hajime Hosoi and can
be grown in DMEM with 10% FBS (23).
HX170c
HX170c was established from a paratesticular tumor of a 5-year-
old Caucasian male. The patient had been previously treated with
vincristine, adriamycin, cyclophosphamide, and radiotherapy. The
tumor specimen was designated RMS based on the presence of
desmin intermediate filaments, and assigned embryonal histology.
HX170c was established simultaneously as a cell line in culture and
xenograft directly from the biopsy of a local recurrence 2 months
prior to the patient’s death. At early passages, HX170c was cul-
tured in vitro on a lethally irradiated layer of mouse fibroblast 3T3
cells; the cell line was later tested and found to contain only human
cells. While the tumor biopsy was positive for desmin staining, the
HX170c cell line was almost completely negative for this marker
when cultured in vitro, except when grown to almost complete
confluence. Interestingly, HX170c subcutaneous mouse xenografts
regained desmin positivity and also appeared histologically similar
to the initial tumor biopsy. HX170c cells are near diploid (50± 6)
(24).
JR-1
JR-1 was derived from a lung metastasis of a 7-year-old female
with a primary uterine mass, previously treated with vincristine,
cyclophosphamide, dactinomycin, and radiation therapy (25). It
has a poorly differentiated embryonal histology, based on his-
tological appearance of the biopsy specimen. This cell line was
grown in RPMI-1640 medium supplemented with FBS. Chromo-
some analysis revealed a near tetraploid number of chromosomes,
ranging from 44 to100 per cell, with 80% showing chromoso-
mal alterations, the most common of which was 13q−. JR-1 cells
have been shown to have mutation of the TP53 gene (26). Anti-
body staining showed similarities between the cell line and the
original tumor, as both stained positive for desmin, vimentin, gly-
colipid, ganglioside Gq, thy-1 and Gp44; and negative for GFAP,
cytokeratin, neurofilament RT97, and myoglobin.
KF-RMS-1
KF-RMS-1 has an embryonal histology (based on the histologic
appearance of its tumor source) and is derived from a bone marrow
metastasis. It is grown in DMEM with 10% FBS (22).
RD
RD was derived directly from biopsy specimens of a 7-year-old
female with a pelvic RMS previously treated with cyclophos-
phamide and radiation and found to have refractory disease (27). It
has an embryonal histology based on histologic appearance of the
tumor biopsies and the cultured cells, and 51-hyperdiploid chro-
mosomes. RD has been shown to have amplification of the MYC
oncogene (28), Q61H mutation of NRAS (29), and homozygous
mutation of TP53 (30, 31). Houghton et al. studied tumor size fol-
lowing injections of various chemotherapy agents and found that
RD demonstrated growth inhibition to vincristine and cyclophos-
phamide, but no other agents tested (32). RD was also used to
test tolfenamic acid, and showed decreased tumor size, decreased
cell migration, and decreased expression of Sp specificity tran-
scription factors after treatment (33). As mentioned in the Section
“Discussion,” the cell line TE671, which was originally thought to
be a medulloblastoma line, was later shown through cytogenetic
analysis and DNA fingerprinting to likely be a subclone of RD
cells (34). RD cells are one of the most commonly used cell lines
in RMS research, can be obtained from ATCC, and are grown in
Eagle’s medium with 10% FBS (35).
RH6
The RH6 cell line was established in the laboratory of Dr. Edwin
Douglass at St. Jude’s Children’s Research Hospital (SJCRH) in
Memphis, TN directly from a 16-year-old male with an infra-renal
lymph node (personal communication, Susan Ragsdale, SJCRH).
Of note, it has no relation to the Rh6 xenograft listed in (36). When
evaluated using cDNA microarray analysis of the cell line versus
original tumor, the RH6 cell line did not cluster within the RMS
family of tumors and therefore, is not optimal for testing of this
cancer type (37). More recently, other studies do mention that this
cell line expresses myogenic markers (38).
Of historical and nomenclature import, all of the “RH” cell
lines (sometimes denoted “SJRH”) were generated at SJCRH and
can be obtained from a representative of that institution, or from
Dr. Peter Houghton at Nationwide Children’s Hospital, Colum-
bus, OH, USA who has maintained these lines. However, during
the years in which human RMS cell lines were first being estab-
lished, two separate laboratories were deriving and naming the
cell lines independently. Cell lines established in the laboratory
of Dr. Peter Houghton were generated by directly transplanting
tumor into mice to establish xenografts, and originally labeled
“Rh.” Cell lines established in the laboratory of Dr. Edwin Dou-
glass (and subsequently Dr. David Shapiro) were generated directly
from patient samples and labeled “RH.” The upper or lower case
designations for these cell line names have since been interchanged
in the literature and are no longer preserved.
RH12
RH12 was derived from a xenograft created from a buttock tumor
in a previously untreated patient. The original tumor and corre-
sponding xenograft have an embryonal histology based on their
spindled appearances (36). Chromosome analysis showed the
addition of multiple chromosomes including 2, 3, 7, 8, 9, 10, 11,
12, 13, 18, 21, and dup (1)(q11q31),+del(2)(q23) (39). In a study
whereby tumor growth was measured against various chemother-
apy agents, RH12 showed volume regression with vincristine,
DTIC, cyclophosphamide, doxorubicin, cis-DDP, and busulfan.
No growth inhibition was seen with the use of dactinomycin,
mitomycin-C, or bleomycin (32). RH12 xenografts were also used
to test the effect of vincristine plus topotecan on tumor growth;
the combination showed improvement over topotecan alone but
was no better than vincristine alone, which had progression of
disease in only 1/7 mice tested (40).
Frontiers in Oncology | Pediatric Oncology July 2013 | Volume 3 | Article 183 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hinson et al. Human rhabdomyosarcoma cell lines
RH14
The RH14 xenograft was derived from an inguinal tumor in a
patient previously treated with vincristine, dactinomycin, and
cyclophosphamide, with complete response and no evidence of
disease for 2.5 years, then recurrence. It had an embryonal histol-
ogy based on histologic appearance of the original tumor and the
xenograft, both of which showed differentiation and cross stri-
ations (36). In evaluations of tumor size injections of various
chemotherapy agents, RH14 had complete regression with the use
of vincristine and significant regression after cis-DDP, DTIC, and
mitomycin-C. No growth inhibition was seen with dactinomycin
or doxorubicin (32). It is important to note that RH14 was only
established as a xenograft, and to our knowledge no cell line is
available.
RH36 (ALSO REFERRED TO AS BIRCH)
RH36 has an embryonal histology (based on the histologic appear-
ance of the original tumor) and was derived from a parates-
ticular relapse in a 15-year-old male (41). The PPTP evaluated
RH36 and found tumor xenograft inhibition in response to
cyclophosphamide (41). RH36 has also been referred to as Birch
in the literature (42) and is grown in RPMI-1640 with 10–20%
FBS (43).
RMS559/R31
RMS559 cells were established in the laboratory of Dr. Jonathan A.
Fletcher, Department of Pathology, Brigham and Women’s Hos-
pital, Boston, MA, USA (44, 45). They can be grown in DMEM
with 10% FBS. This cell line was identified to have a V550L FGFR4
mutation by direct sequencing (46).
RMS-YM
RMS-YM was derived from a relapsed abdominal mass of 2-
year-old Japanese boy, at second relapse (47). The tumor was
believed to originate from the urachus and was given an embry-
onal classification based on histology. The patient was treated
with chemotherapy and radiotherapy, but died 3 years later due
to multi-organ metastasis. RMS-YM is capable of forming subcu-
taneous xenografts in nude mice that appear histologically similar
to the primary tumor. These cells stain positive for desmin and
myoglobin. The karyotype of RMS-YM is 55, XY, −1, −2, −7,
+8, −9, −10, −11, −16, −20, −22, +17 mars. Analysis of the
MYCN and RAS genes showed no amplification or rearrange-
ment, nor mutations of the 12th, 13th, or 61st codons of KRAS,
HRAS, or NRAS. TP53 pathway gene analysis showed no muta-
tion of the TP53 gene, but did show upregulation of MDM2 (31).
RMS-YM also shows overexpression of FGFR1, located in 8p11.2
and is grown in RPMI-1640 with 10% FBS (28).
RUCH2
RUCH2 was derived from a 15-month-old female with a botryoid
RMS of the vagina (48). It was originally established as a xenograft,
then grown in cell culture. Karyotype at passage three revealed
55, X, –X, +7, +inv(7)(q11q32), +8, +8, +12, +13, +13, +19,
+20, +21/55, idem, del(20)(q13) [cp40], almost identical to the
primary tumor. It can be grown in DMEM supplemented with
10% FBS.
RUCH3
RUCH3 was derived from a patient with relapsed embryonal RMS.
This cell line is first mentioned in the original reference for RUCH-
2 cell line, and was found to express PAX3 but not MYF3 or MYF5
(48). It can be grown in DMEM supplemented with 10% FBS.
SCMC-RM2 (AND SUBCLONE SCMC-RM2-1)
SCMC-RM2 was derived from the bone marrow of an 11-year-old
female with relapsed, metastatic embryonal RMS. This patient had
a primary tumor in her right abdominal wall with extensive mar-
row involvement. The tumor was classified as embryonal based
on the presence of cytoplasmic longitudinal fibers and cross stri-
ations, as well as cell appearance using electron microscopy. She
achieved remission with standard chemotherapy but relapsed and
died 11 months later after diagnosis. Tumor cells from her bone
marrow at relapse were obtained and cultured as SCMC-RM2.
Subsequently, at passage 20, a parent cell line was cloned in soft
agar and SCMC-RM2-1 was isolated. Both cell lines stain positive
for muscle markers including desmin, vimentin, myoglobin, and
actin. Interestingly, molecular and cytogenetic evaluation revealed
amplification of the MYCN gene with overexpression of MYCN
mRNA, which was also found in the primary tumor (49). SCMC-
RM2 and its subclone can be grown in RPMI-1640 with 10%
FBS (50).
SMS-CTR
SMS-CTR was derived from an untreated 1-year-old male with
a pelvic mass near the prostate. The original biopsy specimen is
histologically consistent with a poorly differentiated embryonal
RMS. This cell line was established by Dr. Patrick Reynolds in
1979. Cytogenetics were performed on this line in the 10th pas-
sage and showed hypertriploid chromosomes, with translocations
involving t(1;13)(q21;q14) and t(2;13)(p25;q14) (51). It is impor-
tant to point out that these are not the characteristic translocations
associated with alveolar RMS. Though FOXO1 does localize to the
13q14 region, Northern blot studies of this line with a FOXO1
probe failed to show any evidence of a novel-sized transcript, thus
suggesting that FOXO1 is not affected by these translocations (52).
TTC442
TTC442, also occasionally called A91 in the literature, has an
embryonal histology and is grown in RPMI-1640 with 10–
20% FBS. This cell line was originally obtained from the lab-
oratory of Dr. Tim Triche of Children’s Hospital Los Angeles
(CHLA) (43, 53).
TTC516
TTC516, also known as A995 in the literature, has an embryonal
histology and is grown in RPMI-1640 with 10–20% FBS. This cell
line was originally obtained from the laboratory of Dr. Tim Triche
of CHLA (43, 53).
ALVEOLAR RMS CELL LINES
CW9019
CW9019 has an alveolar histology and was developed by Dr. Jaclyn
Biegel at the University of Pennsylvania, Philadelphia, PA, USA. It
can now be obtained from Dr. Frederic Barr at the National Can-
cer Institute, Bethesda, MD, USA (personal communication, Dr.
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Frederic Barr). CW9019 has a stable reciprocal translocation of
t(1;13), expresses the resulting PAX7-FOXO1 fusion protein and
is grown in DMEM with 10% FBS (28). Unlike the typical PAX7-
FOXO1-containing tumor, this line does not show amplification
of the PAX7-FOXO1 fusion gene (54).
D-RHA1
D-RHA1 has an alveolar histology and was originally described in
(43), having been obtained from Dr. W. Benedict of M.D. Ander-
son Cancer Center. It is grown in RPMI-1640 with 10–20% FBS.
KFR
KFR was derived from a bone marrow metastasis of a 13-year-
old female and designated RMS based on positive staining for
vimentin and desmin. Alveolar histology was assigned based
on morphology and upon identification of the t(2;13)(q37;q14)
translocation, expressing the resulting PAX3-FOXO1 (formerly
known as PAX3-FKHR) fusion protein (55). Although there was
a time that the 2q breakpoint was assigned to q35 or q37, this has
now been resolved as a q35 breakpoint, so that the translocation
would now more correctly be stated as t(2;13)(q35;q14). KFR is
grown in modified DMEM with 10% FBS (22).
RH5
RH5 has an alveolar histology and has been cited in a study of the
role of PDGFR-A (56).
RH10
RH10 was derived from a 15-year-old female with a perineal
tumor at relapse; she had previously received extensive chemother-
apy with vincristine, cyclophosphamide, dactinomycin, and dox-
orubicin. RH10 was first established as a xenograft. The result-
ing cell line is hyperdiploid and cytogenetic analysis revealed
t(2;13)(q35;q14) (57). Although the tumor from which RH10
was originally derived was described as having poorly differenti-
ated embryonal histology, in another publication from the SJCRH
group at the same time, this tumor was diagnosed as mixed alveo-
lar/embryonal or monomorphous round cell. With the presence of
the t(2;13) translocation, it should not be called embryonal RMS,
but either mixed or alveolar RMS (39). After injections of various
chemotherapy agents, complete tumor regression was seen after
administration of L-PAM, but only transient growth inhibition, if
any, to the other agents tested (58). RH10 has also been evaluated
by the PPTP and found to have intermediate response activity to
vincristine and high response to cyclophosphamide (41).
RH18 (FUSION-NEGATIVE AND FUSION-POSITIVE VARIANTS)
The RH18 cell line was generated from a xenograft derived from a
tumor from a previously untreated 2-year-old patient with a per-
ineal RMS assigned as embryonal histology. Interestingly, there was
a small amount of alveolar histology in the tumor (although the
xenograft from which the cell line is derived was entirely embry-
onal) (36). At the time, such a mixed presentation often received a
final diagnosis of embryonal RMS, though today the mixed tumors
are considered an intermediate subset in which a fraction have the
PAX-FOXO1 fusion.
RH18 cell-line chromosome number ranges from 70 to 80
per cell, and cytogenetic abnormalities include del(1)(p22),
der(3)t(3;?)(p14;?), del(6)(q24), and der(22)t(1;22)(q31;q11)
(57). In the original cytogenetic characterization of this cell line,
a t(2;13) translocation was identified in a later passage of a
melphalan-resistant population (39). This sub-line also had cyto-
genetic markers in common with an earlier passage, suggesting
that a translocation-bearing clone was selected (or arose) during
culture. This finding is consistent with the presence of two avail-
able cell lines called RH18 – one fusion-negative (59) and one
fusion-positive (60). Indeed an experiment comparing the parent
xenograft to tumor selected for resistance after a large single dose
of vincristine did show near tetraploidy (with numerous structural
abnormalities) in the parent tumor, with all normal diploid cells
noted in the resistant xenograft (61). This supports the idea that
the original tumor, from which the xenograft was directly derived,
had multiple stem lines.
The RH18 cell line also harbors amplification of the 12q13–
15 region (including MDM2) (62), although unpublished data
shows that the amplicon is present in the fusion-negative, but not
fusion-positive, version of RH18 (personal communication, Dr.
Frederic Barr). Clearly, Short Tandem Repeat (STR) analysis (see
Section “Potential Pitfalls”) of the RH18 variants would be helpful
to prove their relationship to the original xenograft, and users of
these cell lines are well-served to determine which variant they are
employing in their experiments.
When tumor volumes were measured following injections of
various chemotherapy agents, RH18 showed growth inhibition
with vincristine, cyclophosphamide, dactinomycin, doxorubicin,
L-PAM, DTIC, cis-DDP, and mitomycin-C. No tumor growth
inhibition was seen with bleomycin or busulfan (32). When eval-
uated by the PPTP, RH18 showed intermediate response activity
to vincristine and high response to cyclophosphamide (41).
RH28 (DERIVED FROM THE SAME PATIENT AS RH3)
The RH28 cell line was derived from a xenograft of tumor tis-
sue obtained from an axillary node metastasis in a previously
untreated 17-year-old male. The tumor and subsequent cell line
have a poorly differentiated alveolar RMS histology. RH28 cells are
near tetraploid and harbor a t(2;13)(q35;q14) translocation (57).
Evaluation of RH28 proliferation in vitro shows that between pas-
sages 59–63, doubling time progressively increases until growth
stops completely, and the cells appear to senesce. Further, these
cells are multinucleated and show morphologies comparable to
normal myoblasts (63). RH28 had complete volume regression
with vincristine and L-PAM and significant growth inhibition with
cyclophosphamide, doxorubicin, and dactinomycin (58). When
tested by the PPTP, RH28 showed high response to both vincristine
and cyclophosphamide (41).
There exists a sub-line of RH28, denoted RH28/LPAM, which
was generated from RH28 cells in xenografts exposed to increasing
doses of melphalan. RH28/LPAM cells are available for use and do
not differentiate or stop proliferating with time (61). There are also
available cells designated RH3, which have the same DNA break-
point and pattern of DNA polymorphisms as RH28 cells (64).
Indeed the RH3 cell line was developed by the Douglass labora-
tory from the same patient from which the RH28 xenograft was
developed. The RH3 cell line has no relation to the Rh3 xenograft
described in (36).
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RH30 (DERIVED FROM THE SAME PATIENT AS RMS13) AND RH30R
The original Rh30 xenograft was established from an overnight
culture of bone marrow obtained from a 16-year-old male with
untreated metastatic alveolar RMS. The xenograft tumor was wild-
type for TP53. The RH30 cell line was derived from the same
patient bone marrow sample maintained in culture in the Douglass
laboratory. The RH30 cell line expresses the t(2;13) translocation
(39) and chromosomal analysis showed near-triploid chromo-
somes, between 51 and 87 (65). This line also has amplification of
the 12q13–q15 region involving CDK4 and surrounding loci (66–
68), and a heterozygous mutation of the TP53 tumor suppressor
(30, 31, 65). An independent cell line, RH30R, was derived from
a xenograft, made from this same patient, at the time of relapse
(41). The relapse xenograft and the cell line from the xenograft
both have the same TP53 mutation as the original RH30 cell line.
RH30 and RH30R are cultured in RPMI-1640 with 10% FBS.
When the RH30 xenograft was tested with various chemother-
apy agents, it showed complete regression using vincristine and
L-PAM, significant growth inhibition after cyclophosphamide, but
no growth inhibition with dactinomycin or doxorubicin (58). The
PPTP evaluated the RH30 cell line and found it to have high
response activity to vincristine and cyclophosphamide (41). A
third experiment used the RH30 cell line to test the combination
of topotecan plus vincristine against tumor growth. The combina-
tion showed better tumor control than topotecan alone but was no
better than vincristine alone, where 0/5 mice tested had tumor pro-
gression (40). The RH30 cell line was also used to investigate the
anti-tumor effects of tolfenamic acid. After treatment, RH30 cells
showed decreased growth, decreased cell migration, and decreased
expression of the PAX3-FOXO1 fusion protein (33).
An alveolar RMS cell-line labeled RMS13 (39, 69) is thought by
some investigators to be related to RH30, perhaps derived from the
same patient tumor as RH30, but this is not clear. Other studies
have presumed RMS13 and RH30 to be independent entities (70).
Finally, another cell line has been distributed with the name of
RH30 (personal communication, Dr. Frederic Barr). Of interest,
this other line still has the 12q amplicon but does not have the
PAX3-FOXO1 fusion (unpublished data, Dr. Frederic Barr). STR
analysis would help clarify the identity of both the RMS13 and
fusion-negative RH30 lines.
RH41 (DERIVED FROM THE SAME PATIENT AS RH4)
RH41 was established by the Houghton laboratory from a
xenograft of a lung metastasis from a previously treated 7-year-old
female patient with alveolar RMS. RH41 was originally designated
as alveolar by histology, and more recently has been shown to
harbor the t(2;13) translocation (71). RH41 also harbors muta-
tion of the TP53 gene (26). RH41 was tested by the PPTP and
showed intermediate response activity to both vincristine and
cyclophosphamide (41).
The cell line designated RH4 was developed from the same
patient by another laboratory at SJCRH (personal communica-
tion, Dr. Peter Houghton), in which the tumor specimen was
placed directly into tissue culture. These cells designated RH4
possess the t(2;13)(q35;q14) translocation (72) and have ampli-
fied, overexpression of EYA2 (28). RH4 cells are cultured in RPMI
supplemented with 10% FBS.
RH65
RH65 was derived from 18-year-old female with a relapsed RMS;
it has an alveolar histology based on the original tumor (41).
RMZ-RC2
RMZ-RC2 was established as a subclone of the RMZ cell line,
which was derived from a bone marrow metastasis of a 2-year-
old male with alveolar RMS; the child had been treated prior
with chemotherapy and radiation (73). RMZ-RC2 can be grown
in DMEM with 10% FBS. Chromosomal analysis showed near
tetraploid range chromosomes with numerous monosomies and
double minutes (65). Both the PAX7-FOXO1 fusion gene and
MYCN were found amplified (65, 72). RMZ-RC2 cells treated
in culture with 2–5 Gy of radiation show dose-sensitive increases
in the expression of myosin and the percentage of multinucleated
cells, both markers of differentiation (74).
TC212
TC212 has an alveolar histology (based on histology of the tumor
specimens) and was derived from the bone marrow metastasis
of a 16-year-old male who relapsed 5 months after multi-agent
chemotherapy and radiation (51). Chromosomal analysis revealed
multiple translocations, inversions, and deletions including what
was thought to be t(2;13)(q37;q14). Although the 2q break-
point was assigned to q35 or q37, this has now been resolved
as a q35 breakpoint, so the translocation in TC212 should cor-
rectly be described as t(2;13)(q35;q14). TC212 cells are grown in
RPMI-1640 supplemented with 10% FBS.
RMS CELL LINE IMPOSTERS
A204
A204 was previously (but no longer) listed in the ATCC catalog
as an RMS cell line. However in 1998, A204 cells were found to
lack expression of myogenin, MyoD, or desmin, suggesting that
either they were not of RMS origin or that with passaging in cul-
ture there was down-regulation of myogenic genes (23). These
observations were especially compelling, since a prior immuno-
histochemical study found that most RMS tumor samples (but not
normal adult muscle including skeletal muscle) expressed MyoD
(75). In 2002, A204 cells were found to have a SMARCB1 (SNF5)
mutation, consistent with its classification as a rhabdoid line (76).
A673
A673 was also previously (but no longer) listed in the ATCC cata-
log as an RMS cell line. However, like A204 cells, in 1998 these cells
were found to not express myogenic markers (23). In 2003, A673
cells were found to express the EWS-FLI1 fusion gene, indicating
the cell line is derived from a Ewing sarcoma (77).
RH1
The RH1 cell line was derived from a patient tumor specimen
grown directly into tissue culture. The tumor was of the hand,
described in a pathology report to be consistent with alveolar
RMS by histologic criteria (personal communication, Dr. Peter
Houghton). RH1 has no relation to the Rh1 xenograft described
in (36). In 1998, RH1 was noted to lack expression of the myogenic
markers myogenin, MyoD, and desmin (23). In 2008, using gene
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expression profiling the PPTP determined RH1 to cluster with
tumors in the Ewing sarcoma family (4). RH1 was later verified to
express the EWS-FLI1 fusion characteristic of the Ewing family of
tumors (78). In retrospect, it is not clear whether RH1 was conta-
minated by a Ewing cell line or mislabeled, however the PPTP has
excluded RH1 from future RMS studies (4).
CULTURE OF RMS CELL LINES AS RHABDOSPHERES VERSUS
ADHERENT CELLS
While all above mentioned studies propagated RMS cell lines as
adherent cells or xenografts, Walter et al. recently described a
method of culturing rhabdospheres in suspension (79). In this
method, spheres are grown by placing human embryonal RMS
cell lines into SC serum free medium with neurobasal medium and
10 ng/ml EGF, 20 ng/ml b-FGF, and 2× B27. In this study, RD cells
were injected as adherent cells or spheres into mice, whereby tumor
growth was measured over weeks. Sphere-derived tumors grew
sooner, 40 days after injection, as opposed to 80 days after injec-
tion with the adherent cells. Sphere-derived tumors also required
fewer cells for injection than adherent cells, indicating that rhab-
dospheres are more tumorigenic than adherent cell cultures. When
stem cell genes associated with the stem cell phenotype were
assessed using real-time PCR, sphere cultures had significantly
higher expression of these genes than adherent cells, consistent
with the premise of stem cell enrichment. Further, when treated
with retinoic acid or DMSO, sphere cultures showed greater dif-
ferentiation toward myocytes, neuronal cells or adipocytes, again
indicating higher cancer stem cell potential in lines grown as rhab-
dospheres versus adherent cells. These data are compelling and
may lead to changes in how RMS cell lines are grown for use in
preclinical experimentation.
POTENTIAL PITFALLS
Several potential problems arise when using cell lines derived from
human tumors in vitro or transplanted into mice as xenografts.
One possibility is that tumors can be contaminated by murine stro-
mal cells, thereby potentially affecting the outcome of the study.
To combat this problem, analysis for species-specific LDH isoen-
zymes, as well as evaluating for acrocentric mouse chromosomes,
can be performed. For example, Hazelton et al. cultured rhab-
domyoblasts from the cell lines RH10, RH18, and RH28 and found
human specific isoenzymes of LDH present in the lines, without
evidence of murine LDH. In this same study, metaphase spreads
were analyzed for acrocentric mouse chromosomes, and none of
the three cell lines evaluated showed murine cells (57).
A second problem is that there may be discordance between
the original tumor and the resulting cell lines or xenografts. To
evaluate for this, one can perform gene expression microarray
analysis. In 2008, the PPTP published a report using microarray
analysis to analyze gene expression of the RMS cell lines RH10,
RH18, RH28, RH30, RH41, RH65, and RD and compared expres-
sion profiles to a similar number of RMS specimens representing
both alveolar and embryonal RMS. After exclusion of immuno-
surveillance genes (such as macrophage or B-cell markers), the
cell lines resembled the other human RMS specimens (4). A sim-
ilar analysis was performed using cDNA microarray analysis of
the RMS cell lines RH1, RH6, RH10, RH12, RH14, RH18, RH28,
RH30, RH36, and RH41. These analyses were compared to cDNA
of primary tumors and all clustered appropriately by tumor type
except RH1 and RH6 (37). Further cDNA microarray analysis
done by Khan et al. showed comparisons between alveolar cell lines
RMS13, RH3, RH4, RH5, RH18, and RH28 (69). Missiaglia et al.
performed cDNA microarray analysis and gene expression profiles,
and compared these profiles to primary tumors on the RMS cell
lines RD, RMS-YM, RUCH2, RUCH3, RH4, RH18, RH30, RH41,
and CW9019 and showed high concordance as well (28). A recent
study describes an approach to develop xenografts directly from
patient tumors, then test them for genomic similarities (80). In this
study, after surgical resection from human subjects, tumors were
either implanted into immune-compromised mice as xenografts
or analyzed for histology, mutational analysis and gene expression
profiles. Xenografts were later surgically resected and implanted
into a second set of mice. Xenograft specimens from first and sec-
ond generation implantations underwent similar analysis as the
original patient tumor sample. This approach serves as a good
model for evaluating and validating human tumor xenografts,
which may help produce preclinical data more closely mirroring
later clinical outcomes
A third problem is the situation in which two cell lines with dif-
ferent names are apparently from the same tumor, such as RH36
and Birch, RH30 and RMS13. This situation can represent two
different nomenclatures or possibly contamination of one cell line
with the other. In addition, although RH3 and RH28 appear genet-
ically identical by fusion breakpoint and STR analysis (64, 81), it
is not clear whether the two cell lines were derived from the same
tumor from the same patient on the same date. In either case,
the two lines may share much of their genetics but may also have
diverged biologically due to continued growth as separate cul-
tures. There are also instances where two distinct lines have the
same name, but have different genetics. For example, the “RH18”
cell line can refer to the version not bearing the fusion gene (59), or
the version bearing the fusion gene (60), which may have emerged
from the original cell culture.
A fourth problem is unintentional cross-contamination
between cell lines. It is estimated that 15–35% of all cell lines are
of a different parental origin than assumed, and this results in the
misidentification of cell lines and ultimately the misinterpretation
of scientific data (82–84). For example, the cell line TE671, which
was widely used to study medulloblastoma, was thought to be a
misidentified RMS cell line (RD). This statement stemmed from
similar phenotypic observations and an activating point mutation
in NRAS gene which was found both in TE671 and RD (34). This
hypothesis was confirmed with a cytogenetic study of these cell
lines (85). In addition, three esophageal adenocarcinoma cell lines
were recently found to derive from other tumors (86).
Because of the problems described above, and no historical
standard method to validate cell lines, the method of STR profil-
ing was suggested as an international reference standard for cell
line authentication (87). STRs (or microsatellite repeats in DNA)
consist of 2–6 base pair repeats that differ from individual to indi-
vidual (84). In this method, commercially available primers are
used to amplify a number of polymorphic STR loci, resulting in a
cell-line specific “fingerprint” that is recorded as a numerical code
in a reference database. The simplicity of the code, reproducibility,
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and low cost of this method are the strengths supporting its
use as a standard of cell line authentication (87). Indeed, several
scientific journals including those managed by the American Asso-
ciation for Cancer Research are requiring that articles submitted
for peer review contain documentation of cell line authentica-
tion (see http://www.aacrjournals.org/site/AuthServCtr/cell_line_
auth.xhtml). On the other hand, it is important to acknowledge
the limitations of STR in cell line authentication. For example, in
a study of four human leukemia cell lines grown under variable
culture conditions, STR profiles changed in two of the four cell
lines due to subclone outgrowth (84). Thus, STR profiling is an
important tool for cell-line validation, but has limitations, espe-
cially in tumor cell lines subject to experimental conditions that
could alter cellular genetics. Other features including myogenic
markers, enzyme isotypes, and cytogenetic analysis can further
assist in validation of RMS cells when differences are found in
STR loci (57, 84). Table 3 summarizes the validation methods that
have been employed for human RMS cell lines. The cell lines with
known and published STRs are listed in Table 4.
DISCUSSION
Numerous RMS cell lines are available for use in basic research
and preclinical testing. These cell lines differ markedly in their
histologies, origins, karyotypes, degree of treatment prior to devel-
opment, and the levels to which these lines have each been vali-
dated and compared to their tumors of origin. This information
is of critical importance when choosing a cell line for study. For
example, evaluation of results of studies performed to date on the
available cell lines shows a trend that lines derived from tumors
previously treated with extensive chemotherapy and/or radiation
are then less susceptible (or only transiently so) to standard agents.
These previously treated cell lines would therefore be optimal for
preclinical testing of new agents proposed for use in relapsed or
refractory disease. These further progressed tumors may also be
easier to establish in culture than primary tumors. It is necessary
to ensure that cell lines used in preclinical trials closely resem-
ble the tumors from which they were derived. While some data is
currently available that validates several lines, this work is ongoing
and will surely continue to develop as the use of cell lines and RMS
xenografts increase in pediatric oncology research.
When examining RMS cell lines as a whole, there is a surprising
lack of cell lines derived from primary, untreated RMS tumors.
Indeed, the majority of both embryonal and alveolar RMS cell
lines are established from tumor relapses or distant metastases.
Cells that arise from relapses or metastases (in addition to any
adaptations as the result of radiation and/or chemotherapy given
to the patient) have genetic changes distinct from the primary
tumor, and may be easier to establish in culture than cells from
primary tumors. Therefore, applicability of these lines in preclini-
cal studies examining RMS primary tumor biology is questionable.
This gap in our understanding of RMS reveals a significant chal-
lenge to researchers that routinely use RMS cell lines for preclinical
research. How can we make significant strides to identify therapeu-
tic targets when the reagents available do not accurately represent
the biology of the primary tumor? Has RMS research been hin-
dered by an excess of false negative hits in pharmacologic and
genetic screens due to these cell-line adaptations?
Table 3 | RMS cell lines: validation methods performed to date.
Cell lines LDH
isoenzymes
Microarray
analysis
Short tandem
repeat
EMBRYONAL HISTOLOGY
CCA – – –
CT-TC – – –
HX170c – – –
JR-1 – – –
KF-RMS-1 – – –
RD – Yes Yes
RH6 – – –
RH12 – Yes –
RH14 – Yes –
RH36 (Birch) – Yes –
RMS559/R31 – – –
RMS-YM – Yes –
RUCH2 – Yes –
RUCH3 – Yes –
SCMC-RM2 – – –
SMS-CTR – – Yes
TTC442 – – –
TTC516 – – –
ALVEOLAR HISTOLOGY
CW9019 – Yes –
D-RHA1 – – –
KFR – – –
RH5 – Yes –
RH10 Yes Yes –
RH18 Yes Yes Yes
RH28 (RH3) Yes Yes Yes
RH30 (RMS13) – Yes Yes
RH41 (RH4) – Yes Yes
RH65 – Yes –
RMS13 – Yes –
RMZ-RC2 – – –
TC212 – – –
In summary, it will be important for RMS scientists, as a com-
munity, to critically evaluate the cell lines we use, and identify
approaches to generate improved reagents for future research.
Ideally, human cell lines would be established from primary,
untreated RMS tumor biopsies. Then, any cell lines generated
from subsequent tumor relapse or metastasis could be paired
with the primary cell line as a “matched set.” To our knowl-
edge there are no matched set cell lines publicly available to
RMS researchers. When available, such a resource would sup-
port the study of the genetic and biologic changes in the pri-
mary tumor, as well as the changes leading to recurrence or
metastasis.
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Table 4 | Available RMS cell line short tandem repeats.
Cell line D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX
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RH28 (RH3) 12, 13 31.2, 32.2 10, 11 10, 12 14, 17 7 12, 13 11, 12 18, 25 14, 15.2 14, 17 8, 9
RH30 (RMS13) 12, 15 29, 31.2 10 10, 11 15 9, 9.3 11 12 17, 20 14, 15.2 17, 18 8, 11
RH41 (RH4) 10, 13 29, 31 10, 11 11, 12 17 7, 9.3 8, 9 12, 13 17, 21 13, 15 16, 18 8, 11
RD 11, 15 28, 29 8, 12 10, 11 15, 17 9.3 13 10, 11 17, 23 11, 14 18 9
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